NCT06972888CompletedPhase 2
A Phase II Clinical Study of AC-201 Tablets in Subjects With Plaque Psoriasis
A Multicenter, Randomized, Double-blind, Parallel-group, Placebo-controlled Phase II Clinical Study to Evaluate the Efficacy, Safety, and Pharmacokinetic Profile of AC-201 Tablets in Subjects With Moderate-to-severe Plaque Psoriasis
Source: ClinicalTrials.gov · Last updated 22 May 2025
Brief summary (registry, in English)
The purpose of the study is to evaluate the efficacy and safety of AC-201 tablets compared with placebo in subjects with moderate-to-severe plaque psoriasis
- Status (registry)
- Completed
- Phase (registry)
- Phase 2
- Study type
- Interventional
- Enrollment
- 145 (actual)
- First submitted
- 7 May 2025
- Start date
- 23 Apr 2024
- Primary completion date
- 7 Mar 2025
- Lead sponsor
- Accro Bioscience (Suzhou) Limited
- Diseases
- Psoriasis
- NCT number
- NCT06972888
What you commit to
- Study type: Interventional · Phase 2
- Participants enrolled: 145
- From 23 Apr 2024 to the primary completion date, 7 Mar 2025
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Have received TYK2 inhibitor and lack of efficacy deemed by investigator
- Topical medications/treatments for psoriasis within 2 weeks prior to administration of any study medication
- Systemic medications/treatments for psoriasis within 4 weeks prior to administration of any study medication
- Has received biological treatment (e.g., anti-TNFα, anti-IL12/23, anti-IL17) for psoriasis less than 5 half-lives of treatment prior to administration of any study medication
Other illness
- History or risk of tuberculosis (TB)
Lab values
- Current or history for drug-induced psoriasis (e.g., psoriasis induced by beta blockers, calcium channel blockers, antimalarial drugs, or lithium)
Other
- Other form of psoriasis (e.g., erythrodermic, pustular or guttate)
Who the study is looking for
- -Stable plaque psoriasis (defined as no morphological or severity changes for ≥ 6 month) and meet the following disease severity at screening and baseline: Total PASI score ≥ 12, and Total sPGA ≥ 3, and Total BSA ≥ 10%
- -Candidate for phototherapy or systemic treatment for plaque psoriasis
Age in the registry: 18 years to 75 years · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| The First Hospital of China Medical University Coordinator of this site? Confirm its status | Shenyang | China | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.